RELI Group wins CMS Drug Price Negotiation Oversight Contract
Baltimore, MD (April 29, 2025) – The Centers for Medicare & Medicaid Services (CMS) has awarded RELI Group a five-year contract for Medicare Drug Price Negotiation Program Monitoring, Oversight, Compliance and Auditing (MOCA). The contract value is nearly $60 million. RELI Group was the successful bidder from a pool of seven proposals, adding to its existing portfolio of more than 20 active contracts with CMS.
“We are honored to have been selected by CMS to support this critical initiative aimed at enhancing transparency and accountability in Medicare drug pricing,” shared RELI Group Founder and CEO Mohammad Elias. “At RELI Group, we are deeply committed to advancing CMS’ mission through innovative oversight, compliance, and auditing solutions that strengthen public trust and deliver real impact. We look forward to continuing our partnership with CMS to ensure the success of the Medicare Drug Price Negotiation Program.”
RELI Group performs monitoring, oversight, compliance and auditing services on a number of existing contracts for CMS, including RVC, AMS, ASIC, MRAC and CSMM. The company’s expert staff includes medical directors, physicians, nurses, medical coders, clinical abstractors and quality specialists with the knowledge and expertise necessary to support this vital work.
Work on this contract begins on May 2, 2025.
